Loading stock data…
AN2 Therapeutics (ANTX)
$5.20+0.06 (+1.17%)
Market ClosedLast close Jun 26
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AN2 Therapeutics, Inc. in the Healthcare sector is trading at $4.94 with a market capitalization of $177M. Wall Street consensus targets $9.00 (1 analysts), implying a +82.2% move over the next 12 months. The stock is currently 29% below its 52-week high of $6.91, remaining 105.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +82.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.55M↓ | -$9.32M↑ | -$10.04M↓ | -$7.22M↑ | -$11.54M |
| Net Income | -$10.03M↓ | -$8.71M↑ | -$9.35M↓ | -$6.46M↑ | -$10.65M |
Peer Comparison
JNJUNHPFE
Fundamentals
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for pa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$177.38M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.26%
Volume
Today's trading volume
3.65M
Recent News
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
Here is how Allogene Therapeutics (ALLO) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.